There’s an increasing amount of scientific evidence pointing to the importance of good sleep hygiene for cognitive health in retirement.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The right choice depends on client preferences about cost predictability and risk management.
Federal grants have helped keep Medicare Part D prescription drug costs down, but they’re set to end next year.
The projection is up 7.5% from last year, and marks the largest annual jump in more than a decade, according to a new Fidelity study.
They can result in many thousands of dollars in excess costs and even jeopardize access to care in the worst cases.
Psychedelic medications, backed by the White House, may alter the prognosis for people with treatment-resistant depression, but risks remain.
Labor-intensive services such as gardening, home healthcare and day care and preschool were all significant drivers of inflation.
Retirement planning is much more dynamic than a decade ago, and financial advisors are rewriting the playbook.
The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly’s recently published study.
Evercore ISI analysts said in a note they “see no meaningful revenue opportunity” for Moderna in hantaviruses.
A recent rule change requiring higher earners to use Roth accounts for catch-up contributions has some adopting a different strategy.
Scary stats about the cost of health care in retirement drive many to simply ignore the issue, resulting in missed planning opportunities.
HSAs are lauded for their triple-tax benefits, and can be useful for wealthy clients, even if they don’t do much to improve American health care.
Getting the most out of Medicare requires regular reevaluation and carefully balancing risks with costs, experts say.
After years of aggressive expansion, many Medicare Advantage plans are recalibrating popular extras and changing costs.
Science Corp., a brain-implant startup developing a device that can enable blind people to see again, just raised $230 million from investors.